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required permanent drug discontinuation due to acute infu-
sion-related reactions, which occurred as grade 3 events in 
two patients. PK analysis indicated that the targeted drug 
exposure based on preclinical models was not achieved by 
the tolerated doses and PK modeling suggesting that doses 
at least fivefold higher would be necessary. No anti-tumor 
activity was observed.
Conclusion Based on the safety data, the risks associ-
ated with the likelihood of significant cytokine-mediated 
infusion reactions at higher doses, the projected high dose 
necessary to affect on the biological target and the lack 
of anti-tumor activity at the doses explored, the trial was 
prematurely terminated without determining a formal 
maximum tolerated dose. Further clinical development of 
PF-04605412 has been discontinued.
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Introduction
Integrins are a family of transmembrane glycoprotein 
receptors that provide docking sites for endothelial and 
inflammatory cells and thereby regulate interactions 
between the cell and the extracellular matrix. Integrins also 
play a key role in signal transduction [1, 2]. Each integrin 
is composed of an α and a β transmembrane subunit, which 
combine to form more than 20 distinct integrins that are 
expressed in malignant and normal cells. The specific pair-
ing of α/β subunits defines the function of the protein [3, 4].
Given the role of integrins in cancer cell proliferation, 
invasion, metastasis and angiogenesis, they are consid-
ered a potential target in anticancer drug development. 
One obvious challenge for targeting integrins in oncology 
Abstract 
Purpose A first-in-human clinical trial of a fully human, 
Fc-engineered IgG1 monoclonal antibody targeting integ-
rin α5β1 was conducted to evaluate tolerability, maximum 
tolerated dose, pharmacokinetics, pharmacodynamics and 
preliminary anti-tumor activity.
Methods Escalating doses of PF-04605412 were given 
IV on day 1, 28 and every 2 weeks thereafter to patients 
with advanced solid tumors until disease progression or 
unacceptable toxicity. Sequential dose cohorts were evalu-
ated based on a modified 3 + 3 dose-escalation design. The 
starting dose was 7.5 mg based on preclinical data.
Results Thirty-three patients were enrolled to six dose 
levels (7.5, 11.25, 16.9, 34, 68 and 136 mg). Twenty-three 
patients were evaluable for the primary endpoint (deter-
mination of the maximum tolerated dose). Five patients 
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is their widespread expression in non-cancerous cells [5]. 
Integrin α5β1 plays key roles in cell adhesion, migration, 
proliferation, differentiation, and survival in both normal 
and tumor cells [6–8]. In human cancers, the expression 
of integrin α5β1 and fibronectin is significantly and coor-
dinately enhanced on tumor blood vessels and in tissues 
stimulated by growth factors and cytokines. Integrin α5β1 
is also frequently observed in many types of cancer and 
tumor-associated macrophages and fibroblasts. Preclinical 
data with agents that disrupt the functions of integrin α5β1 
support its targeting as an anti-angiogenic strategy for the 
treatment of human malignancies [9, 10].
Clinical data have been previously reported for volocixi-
mab (M200, PDL Biopharma and Biogen Inc), a chimeric 
(82 % human, 18 % murine) IgG4 monoclonal antibody 
(mAb) against α5β1 integrin. Overall good tolerance, 
with minor constitutional adverse events, was described in 
a phase I study testing doses up to 15 mg/kg QWK [11]. 
Although single-agent anti-tumor activity was disappoint-
ing [12], the good safety profile led to a trial combining 
volociximab with carboplatin/paclitaxel in non-small cell 
lung cancer [13].
PF-04605412 is a fully human, Fc-engineered anti-α5β1 
IgG1 mAb with anti-angiogenic properties. PF-04605412 
potently inhibited integrin α5β1-mediated cell spread-
ing, adhesion and tube vessel formation, and induced sig-
nificantly greater antibody dependent cellular cytotoxicity 
(ADCC) against endothelial cells or α5β1-bearing tumor 
cells when compared with wild-type IgG1 anti-α5β1 
mAb. PF-04605412 exhibited robust single-agent anti-
angiogenesis and anti-tumor properties, with regression in 
tumor size and prolongation of survival in xenograft mod-
els, which was associated with macrophage tumor infil-
tration, increased caspase-3 and decreased Ki67 signal in 
the tumor. The mechanism of action of PF-04605412 was 
studied in transgenic knock-in mouse models in which the 
coding sequence of integrin α5 was replaced by the human 
counterpart, with demonstration of dose-dependent tumor 
growth inhibition [14]. Proof of principle for ADCC has 
been demonstrated for several monoclonal antibodies cur-
rently in clinical use including rituximab, alemtuzumab, 
trastuzumab and cetuximab [15–22]. In order to optimize 
the interaction between antibody Fc domains and FcγRs of 
effector cells, PF-04605412 was engineered with a point 
mutation in the Fc region to enhance ADCC. PF-04605412 
mediates ADCC in preclinical models. PF-04605412 was 
well tolerated in primates up to doses of 100 mg/kg weekly.
We present the results of a first-in-human, open-label, 
dose-escalation study of PF-04605412 conducted at three 
institutions in adults with advanced solid tumors refrac-
tory to standard anticancer treatments. The starting dose 
of PF-04605412 for the first cohort of patients was 7.5 mg, 
which in a 75 kg human adult is equivalent to 1/10 of the 
non-observable adverse event level (NOAEL) dose in 
repeat-dose toxicity studies in primates (1 mg/kg qwk).
Methods
Study drug
PF-04605412 was supplied by the trial sponsor as a ster-
ile solution for intravenous (IV) administration in single 
use 10 mL clear glass vials at a concentration of 10 mg/
mL. The drug was infused in 2 h following paracetamol 
and antihistamine premedication. The second infusion was 
administered 4 weeks later and every 2 weeks thereafter.
Trial design
Main inclusion criteria for the study included: advanced 
solid cancer that has progressed despite currently available 
therapies, Eastern Collaborative Oncology Group (ECOG) 
Performance Status of 0–1, adequate organ function, 
absence of brain metastases and no prior history of signifi-
cant cardiovascular co-morbidities, bleeding disorders or 
vasculitis. Patients on anticoagulant therapy or taking anti-
platelet agents were not eligible. Left ventricular ejection 
fraction and lung diffusion capacity were tested as part of 
the screening procedures.
The primary objective of the study was to determine the 
maximum tolerated dose (MTD) of PF-04605412 and rec-
ommend a dose for further clinical studies in patients with 
advanced solid tumors. Secondary objectives included char-
acterization of the safety and tolerability of the drug, the 
PK profile and the immunogenicity of the compound and to 
describe any preliminary evidence of anti-tumor activity.
Dose escalation used a modified 3 + 3 design. The mag-
nitude of increment in dose in succeeding cohorts depended 
on the presence of grade ≥2 drug-related toxicities. The 
targeted MTD was predefined as that dose level just below 
the dose level resulting in dose-limiting toxicities (DLTs) 
in ≥33 % of patients.
This study was conducted in compliance with the Decla-
ration of Helsinki and in compliance with all International 
Conference on Harmonization and Good Clinical Prac-
tice Guidelines. The trial protocol and any amendments 
were reviewed and approved by the Institutional Review 
Board(s) and Independent Ethics Committee at each of the 
centers participating in the study.
Safety assessments
Safety evaluations included monitoring of adverse events 
(AE) throughout study participation, vital signs, ECG, 
laboratory assessments and physical examinations at every 
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visit. AEs were graded following National Cancer Insti-
tute Common Terminology Criteria for Adverse Events 
(CTCAE), Version 3.0. DLTs were defined as any grade 
3 or higher AE in relation with the study drug (without a 
clear alternative explanation) occurring during the first 
6 weeks (2 infusions) of treatment with PF-04605412.
Pharmacokinetic analysis
Blood samples for PK analysis were drawn at prespecified 
time points over 24 h after the first infusion and on days 
3, 5, 8, 11, 15 and 22 after initial treatment. Further sam-
ples were collected before and 2 h after each subsequent 
infusion. Samples were assayed by QPS, LLC (New-
ark, Delaware, United States) using chemiluminescence 
enzyme-linked immunosorbent assay methodology. Phar-
macokinetic parameters by dose cohort were summarized 
using descriptive statistics and presented in tabular and 
graphical form.
Immunogenicity and biomarker analysis
Serum samples were analyzed for anti-drug antibodies 
(ADA) or human antihuman antibodies using a validated 
analytical assay. Samples for ADA evaluation were collected 
just prior to each dose and monthly up to 3 months after the 
last administered dose. The assay used electrochemilumi-
nescence methodology validated to detect anti-PF-04605412 
antibodies in human serum samples. ADA concentration data 
were listed by dose level, subject and cycle. A cut-off value 
for antibody titers of 4.32 was considered positive.
Additional blood samples were collected at prespecified 
time points for exploratory assessment of changes in cells 
that mediate ADCC response to PF-04605412, by enumera-
tion of natural killer (NK) lymphocytes, defined as CD16+/
CD56+, and assessment of any induced cytokine response 
(including tumor necrosis factor alpha (TNFα), interleukin 
(IL)-1 beta (IL-1 β), interferon gamma (IFNγ), IL-2, IL-4, 
IL-5, IL-6, IL-8, IL-10 and IL-12p70).
Anti-tumor activity
Assessment of preliminary evidence for anti-tumor activity 
by the Response Evaluation Criteria in Solid Tumors version 
1.1 was based on CT or MRI scans performed every 6 weeks.
Results
Population characteristics
Thirty-three patients were treated at six dose levels. Base-
line characteristics of the population are summarized in 
Table 1. Disease progression was the principal reason for 
trial drug discontinuation (n = 21, 63 %). The median 
number of cycles received was 2 (6 weeks of treatment). 
Safety and tolerability
Six dose levels were explored (7.5, 11.25, 16.9, 34, 68 and 
136 mg). Twenty-three patients were evaluated for the pri-
mary endpoint (DLT and MTD). Two dose-limiting events 
(as defined per protocol, grade 3–4 drug-related events as 
per CTCAE v3.0 during the first 6 weeks of treatment) 






Mean (range) 56.4 years (32–74 years)
<65 years 25 75.8
≥65 years 8 24.2
Body mass index







Head & Neck 3 9.1
Non-small cell lung 2 6.1
Cervix 2 6.1






Systemic therapy 33 100
1–2 lines of therapy 6 18.2
3 lines therapy 12 36.4
>3 lines therapy 15 45.5





Liver M1 16 48.5
Lung M1 17 51.5
Bone M1 2 6.1
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were reported: both were cases of grade 3 infusion-related 
reaction (hypersensitivity). One occurred in a patient 
receiving the lowest dose level (7.5 mg) and the other was 
in a patient enrolled to the highest dose cohort (136 mg). 
Although MTD was not achieved based on the formal DLT 
criteria, dose escalation was interrupted after 7 (21 %) 
patients in the study required permanent drug discontinu-
ation due to a drug-related event, mainly hypersensitivity 
or infusion-related reactions (n = 5). These other infusion-
related reactions were grade 2 in severity but with recur-
rences upon resuming drug administration. They were not 
considered as DLT but led to permanent discontinuation 
and were considered at the time of dose escalation.
Infusion-related reactions occurred across all dose levels 
although they were more frequent at the highest dose level 
tested (4/9 patients treated with 136 mg of PF-04605412). 
Symptoms included flushing, hypotension and nausea 
appearing during the first 5–10 min of drug administration. 
Occasionally, bronchospasm and transient grade 1–2 neutro-
penia and thrombocytopenia were observed. The reactions 
were managed with hydrocortisone and antihistamine ther-
apy. Bronchodilators were administered when necessary. 
All the episodes resolved within minutes, except in the case 
of a 68-year-old man with metastatic non-small cell lung 
cancer who, after having the drug infusion interrupted and 
receiving appropriate treatment for the acute reaction, had 
a further episode of grade 3 bronchospasm and hypoten-
sion 20 min later and required a second dose of intravenous 
hydrocortisone. All patients were observed for an additional 
8–24 h after resolution of any hypersensitivity reaction, and 
no residual symptoms were reported at follow-up visits.
Other than the infusion-related reactions, few grade 3 
or higher adverse events secondary to PF-04605412 were 
observed: thrombocytopenia (n = 1), chills (n = 1) and 
increase of gamma-glutamyl transferase (n = 1). One study 
participant died within 30 days of last study drug admin-
istration due to progression of the underlying cancer; no 
deaths were reported as related to the study drug.
Table 2 summarizes the most frequently reported AEs 
(any grade) for all cycles. The most common AEs were 
fatigue (13 subjects), nausea (10), chills (8) and pyrexia (7).
Changes in blood cell count, presumably due to transient 
compartment shifts, were expected as a result of the mecha-
nism of action of the compound. One episode of asympto-
matic, transitory grade 4 thrombocytopenia was observed in 
a 67-year-old Caucasian man after his first cycle of treatment, 
with spontaneous return to baseline levels without medical 
intervention. The episode did not coincide with any other 
symptom such as an allergic reaction to study drug infusion.
Abnormalities of grade 3 or higher in the biochemistry 
blood tests occurred in a total of 11 patients: elevation of 
alanine aminotransferase, alkaline phosphatase, amylase, 
aspartate aminotransferase, hyperglycemia and hypona-
tremia. The majority of these findings were considered as 
not related to the study drug administration. One subject 
receiving 11.25 mg of PF-04605412 had asymptomatic 
grade 4 lipase elevation, thought secondary to the underly-
ing cancer. Most of the laboratory abnormalities reported 
were grade ≤2 in severity.
Pharmacokinetics data
PK analysis of patients across the six dose levels dem-
onstrated a greater than dose-proportional increase of 
PF-04605412 Cmax, AUClast and AUCinf with rising 
doses. Inter-patient variability was high across the differ-
ent cohorts, with a coefficient of variation ranging from 
28–86 % to 11–90 % for AUCinf and Cmax, respectively.
Table 2  Drug-related adverse 
events of any grade observed in 
>1 patient
n % 7.5 mg 11.25 mg 16.9 mg 34 mg 68 mg 136 mg Any dose level, 
grade ≥ 3
Patients treated 33 8 5 3 5 3 9
Dose-limiting events 1 0 0 0 0 1
Fatigue 9 27 1 1 2 1 1 3 0




8 24 1 2 0 1 0 4 2
Nausea 8 24 2 1 1 1 1 2 0
Pyrexia 6 18 4 1 1 0 0 0 0
Vomiting 4 12 1 0 2 0 0 1 0
Flushing 4 12 1 1 0 0 0 2 0
Tachycardia 3 9 0 1 1 0 0 1 0
Dyspnea 2 6 0 0 0 0 0 2 1
Hypertension 2 6 1 0 0 0 0 1 0
Hypotension 2 6 1 0 1 0 0 0 0
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The volume of distribution was mainly restricted to 
the plasma volume. The median half-life of the drug was 
36 h at the highest dose level, with a multiphasic decline in 
serum concentrations. Clearance was rapid and decreased 
with increasing dose levels (3.79 L/h at lowest dose level 
and 0.06 L/h at highest dose administered).
Figure 1 represents the median serum concentration of 
PF-04605412 over time after the first infusion, and Table 3 
summarizes the main PK parameters for the dose levels 
tested.
According to the preclinical studies, the minimal tar-
geted plasma concentration of PF-04605412 for thera-
peutic effect was 8,900 ng/mL. At the 136 mg dose level, 
the mean concentration of PF-04605412 fell below the 
projected efficacious concentration within 96 h (<15 % of 
the dosing interval). Based on extrapolation of drug clear-
ance to higher doses and simulations from the available PK 
data, we estimated that the dose necessary to achieve this 




Anti-PF04605412 antibodies were found in three patients 
(9 %) at titers of 8.15, 9.03 and 14.28 (antibody titers of 
4.32 were used as cut-off value). Neither the presence nor 
the titer of anti-PF04605412 antibodies correlated with 
occurrence of infusion-related reactions and they did not 
appear to alter the PK profile.
Biomarkers of ADCC response
Sequential plasma samples from 20 patients (60 %) were 
suitable for assessment of changes in lymphocyte subpopu-
lations. Results showed poor stimulation of NK (CD16+/
CD56+) subpopulations at the dose levels tested, without a 
clear incremental effect at higher doses (Table 4).
Induced cytokine changes
The levels of TNFα, IFNγ, IL-6, IL-8, and IL-10 increased 
after 1–2 h post PF-04605412 infusion across all dose lev-
els. The median time to reach peak cytokine levels (TCY-
TOmax) ranged from 0.5 to 3 h across doses. Cytokine 
Fig. 1  Median concentrations of PF-04605412 over time for cycle 1 
by dose level
Table 3  Geometric mean (%CV) pharmacokinetic parameters following intravenous doses of PF-04605412 (Cycle 1)
The PK parameters (t½ and AUCinf) could not be estimated for 12 subjects due to inadequate PK profile
N = number of subjects; n = number of subjects contributing to the geometric mean for AUCinf, CL, and Vss
AUCinf area under the plasma concentration–time profile from time 0 extrapolated to infinite time, AUClast area under the plasma concentration–
time profile from time 0 to the time of the last quantifiable concentration, Cmax maximum plasma concentration, CL clearance, NR not reportable, 
SD standard deviation, t½ terminal half-life, Tmax time for Cmax, Vss volume of distribution, %CV percent coefficient of variation
a
 Geometric mean (%CV) for AUCinf, AUClast, Cmax, CL and Vss; arithmetic mean (±SD) for t½; median (range) for Tmax
b
 Geometric mean (%CV) was not reported for n ≤ 2, instead median was reported
Parameters Parameter summary statisticsa for PF-04605412 dose cohort
7.5 mg 11.25 mg 16.9 mg 34 mg 68 mg 136 mg
N, n 7, 2b 4 3, 2b 5, 4 3, 3 6, 5
Cmax (ng/mL) 578.3 (37) 1,229 (27) 1,826 (90) 6,682 (11) 13,400 (18) 34,110 (37)
AUClast (ng h/mL) 4,784 (171) 14,440 (170) 12,930 (103) 149,400 (71) 490,600 (85) 2,047,000 (28)
AUCinf (ng h/mL) 2,000 NR 27,650 160,600 (69) 505,200 (86) 2,053,000 (28)
t½ (h) 2.70 NR 7.27 13.5 (3.99) 19.2 (8.60) 36.9 (3.96)
Tmax (h) 2.00 (1.00–44.7) 3.04 (3.00–5.50) 2.43 (2.05–3.02) 2.52 (2.00–47.4) 2.00 (2.00–2.53) 6.03 (2.25–50.6)
CL (L/h) 3.79 NR 0.95 0.212 (61) 0.135 (58) 0.066 (21)
Vss (L) 13.65 NR 10.87 6.61 (66) 5.91 (22) 3.73 (22)
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levels declined to baseline rapidly thereafter. No detect-
able changes from baseline were observed for IL-1 β, IL-2, 
IL-4, IL-5 and IL-12p70 following the administration of 
PF-04605412.
Anti-tumor activity
A total of 33 patients were evaluated for the secondary 
endpoint of preliminary anti-tumor activity. No objective 
responses were observed in this study. Fourteen patients 
had documented progressive disease at the time of the first 
planned radiological assessment (week 6 of treatment). 
Best response of stable disease for over 24 weeks was doc-
umented for two patients, including a patient with primary 
adenoid cystic carcinoma who discontinued treatment after 
30 weeks with stable disease due to requiring a surgical 
procedure for symptoms related to a benign uterine tumor.
Discussion
This first-in-human study of PF-04605412, a fully human 
anti-α5β1 IgG1 mAb administered to patients with 
advanced solid malignancies, failed to achieve the primary 
endpoint. Although a formal MTD was not reached, medi-
cally significant safety events, consisting of grade 2–3 infu-
sion reactions, were observed at multiple dose levels with 
a trend to worsening as the dose levels increased. Continu-
ous evaluation of the safety events related to the drug and 
emerging data from real-time PK modeling, suggesting the 
dose necessary for eventual target modulation would be 
much higher than the dose levels tested, supported a joint 
decision by the investigators and sponsor to discontinue the 
clinical development of the compound.
Acute infusion-related reactions and constitutional 
symptoms (fatigue, nausea, chills and pyrexia) were the 
most common AEs and were likely related to the mecha-
nism of action of PF-04605412. One of the five evalu-
able subjects (20 %) receiving 136 mg developed an 
adverse reaction to the infusion fulfilling the criteria to 
be considered a DLT, with 4 additional patients at differ-
ent dose levels experiencing varying grades of acute reac-
tions to the drug resulting in permanent discontinuation of 
PF-04605412.
The occurrence of constitutional symptoms is in accord-
ance with previous reports of similar therapeutic agents 
[11]. Reactions to monoclonal antibodies, typically occur-
ring acutely during the first infusion, are a well-described 
effect of this entire drug class, with symptoms ranging from 
mild rigors to systemic anaphylaxis. The rates of hypersen-
sitivity in this study do not differ significantly from those 
of other mAb successfully brought into clinical practice 
as anticancer treatments such as cetuximab and rituximab 
[23]. Administration of various premedication regimens 
and/or adjustments to infusion duration has been used in 
the successful clinical development of other therapeu-
tic mAb. In our study, however, hypersensitivity reactions 
proved to be the major barrier to the delivery of projected 
therapeutic dose levels of PF-04605412. Our attempts at 
intensifying the premedication regimen and modifying the 
duration of the infusion to improve tolerability had limited 
success. We were also unable to define any obvious predic-
tive factors for the development of acute infusion reactions 
to PF-04605412; the presence of antidrug antibodies in 3 
subjects in this study did not correlate with the appearance 
of the adverse reactions, similar to reports on other thera-
peutic antibodies [24, 25].
PF-04605412 was designed to enhance binding to Fc 
receptors for more effective mobilization of effector cells to 
mediate ADCC activity. A transient increase in cytokine pro-
duction (TNFα, IFNγ, IL-6, IL-8, and IL-10) was triggered by 
the study drug, and temporary reductions in peripheral blood 
Table 4  Summary of 
changes in CD16 +/
CD56 + lymphocyte 
subpopulations per dose level
No consistent dose-related 
effects on NK levels were 
observed. (Post-infusion value 
represents the value with 
the greatest difference from 
baseline. Time post-infusion 
indicates when this difference 
was observed)
Dose of PF-04605412 (n = evaluable patients)
16.9 mg (n = 2) 34 mg (n = 3) 68 mg (n = 1) 136 mg (n = 6)
CD16 +/CD56 + cells relative to total lymphocyte count
Mean (CV %)
Baseline 12.65 % (60.61) 20.10 % (47.88) 5.00 % 19.91 % (50.12)
Maximum change post-infusion 11.53 % (65.27) 14.72 % (43.75) 2 % 14.51 % (60.34)
Time to maximum change (h) 
median
2 2 2 6
Total CD16 +/CD56 + cells/μL
Mean (CV %)
Baseline 159.01 (100.92) 181.95 (14.64) 64 164.40 (93.88)
Maximum change post-infusion 183.25 (85.47) 199.65 (20.58) 44.0 138.39 (103.20)
Time to maximum change (h) 
median
85 2 1 1.5
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cell counts, which were an expected pharmacodynamics 
effect of the study drug, were observed. Changes in periph-
eral blood counts were possibly due to cytokine-induced mar-
gination. Interestingly, there was one case of acute and severe 
rapid thrombocytopenia with rapid spontaneous resolution. 
Bone marrow examination of this patient showed normal 
megakaryocytes. However, stimulation of ADCC response, 
indirectly evaluated based on changes in relevant peripheral 
lymphocyte subpopulations, was not observed at the dose lev-
els tested in this study; a potential explanation is insufficient 
drug exposure to create the desired effect.
To understand better the possible causes of PF-
04605412-mediated cytokine release, human endothelial 
cells were co-cultured with purified human PBMC in vitro 
in the presence of PF-04605412 (unpublished data; meth-
ods and results in supplemental material). Levels of IL-6, 
IL-8, IFNγ and TNFα were significantly increased in these 
co-cultures at 4 h after PF-04605412 treatment but these 
cytokines were not induced when exposing either endothe-
lial cells or PBMC alone to the drug. Fab of PF-04605412 
also did not affect the levels of cytokines in this co-culture 
condition. These results support the hypothesis that the 
cytokine levels observed in patients were the consequence 
of PF-04605412-mediated bridging of PBMC and endothe-
lial cells. The short-term cytokine release observed in the 
clinical trial may therefore be evidence of an on-target 
effect of PF-04605412, which nevertheless was not associ-
ated with clinical benefit.
Pharmacokinetic assessments demonstrated more rapid 
drug elimination (terminal half-life 2.70–36.9 h) than 
expected for an IgG1 antibody. A plausible explanation for 
this observation is target-mediated drug disposition, which 
has been observed in other studies with monoclonal anti-
bodies [26, 27]. The dose-dependent increase observed in 
drug clearance would support this hypothesis. Extrapola-
tion of drug clearance at higher doses and simulations gen-
erated based on emerging pharmacokinetics data from the 
patients treated predict that a dose of at least 688 mg would 
be required to saturate α5β1 integrin on peripheral mono-
cytes and, in turn, reach α5β1 integrin in the tumor cells in 
order to produce an anti-tumor effect.
Real-time evaluation of safety, pharmacokinetic and 
pharmacodynamics data emerging from first-in-man stud-
ies is necessary for optimal, efficient drug development. We 
did not find a way to prevent infusion reactions and the data 
emerging from PK modeling predicted that a dose 5 times 
above the tested dose would have been necessary to modu-
late target. This analysis together with a very high likeli-
hood of re-occurring and potentially dangerous cytokine-
mediated infusion reactions with escalating higher doses, 
made us decide to terminate the study before reaching a 
MTD. Moreover, no reliable signs of anti-tumor activity 
were observed at any of the dose levels tested. The risk/
benefit assessment was therefore deemed unfavorable by 
the investigators and sponsor.
Early no-go decisions, as in this case, using all of the 
available information along with realistic and practical pro-
jections of what is likely to occur if the study continues, 
avoid unnecessary exposure of patients to ineffective drugs 
and permit optimization of all resources by academic inves-
tigators and pharmaceutical industry.
Conclusions
In this trial, we were not able to achieve a formal MTD. 
Dose escalation was halted by the investigators and spon-
sors taking the following factors into account: grade 3 
toxicity (acute infusion-related reactions) that could not 
be mitigated by standard measures in the outpatient clinic 
(including changes in infusion duration and various types 
of premedication regimens), the observation that 4 of 9 
patients at the highest dose level tested developed clinically 
significant reactions, and PK modeling that indicated that 
we would need to escalate the dose fivefold more in order 
to achieve predicted target dose levels for target saturation.
This trial highlights the value of vigilant toxicity moni-
toring and real-time PK data and modeling. In the face of 
medically significant events thought directly related to the 
mechanism of action of the drug, and therefore likely to 
be dose-related, further dose escalation was not thought to 
be feasible without placing patients at unacceptable risk. 
Therefore, further clinical development of PF-04605412 is 
not recommended.
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